Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 1, 2014, Pages 71-80

  Seah, Davinia S E ^a   Luis, Ines Vaz ^a   Macrae, Erin ^b   Sohl, Jessica ^a   Litsas, Georgia ^a   Winer, Eric P ^a   Lin, Nancy U ^a   Burstein, Harold J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; DISEASE COURSE; ELECTRONIC MEDICAL RECORD; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FOLLOW UP; HORMONE RECEPTOR BREAST CANCER; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; TREATMENT DURATION; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84893779729     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0008     Document Type: Article

References (37)

1. Dawood S, Broglio K, Gonzalez-Angulo AM, et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 2008;26:4891-4898.
2. Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005;104:1742-1750.
3. Chia SK, Speers CH, D'Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-979.
4. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 2004;31(Suppl 1):S149-161.
5. Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011;29:2144-2149.
6. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
7. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
8. Wang Y, Yin Q, Yu Q, et al. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 2011;130:489-498.
9. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13(15 Pt 1):4429-4434.
10. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008;113:2638-2645.
11. Sanpaolo P, Barbieri V, Genovesi D. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol 2011;37:876-882.
12. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 1987;235:177-182.
13. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
14. Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) 2012;26:688-694, 696.
15. Nielsen DL, Kumler I, Palshof JA, et al. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 2013;22:1-12.
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-444.
17. Bailey CH, Jameson G, Sima C, et al. Progression-free survival decreases with each subsequent therapy in patients presenting for phase I clinical trials. J Cancer 2012;3:7-13.
18. Gennari A, D'Amico M, Corradengo D. Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review. Ther Adv Med Oncol 2011;3:229-232.
19. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-923.
20. Lin NU, Burstein HJ. EMBRACE, eribulin, and new realities of advanced breast cancer. Lancet 2011;377:878-880.
21. Cardoso F, Di LA, Lohrisch C, et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 2002;13:197-207.
22. Seah D, Lin N, Curley C, et al. Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis [abstract]. J Cancer Res 2012;72(Suppl 3):Abstract P6-08-03.
23. Wheler J, Tsimberidou AM, Moulder S, et al. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer 2010;10:46-51.
24. Bernardo G, Palumbo R, Bernardo A, et al. Which benefit from subsequent chemotherapy lines beyond the second for women with metastatic breast cancer? Evidence from a single-center retrospective analysis of survivorship [abstract]. J Clin Oncol 2011;29(Suppl 27):Abstract 255.
25. Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30:3234-3241.
26. Olson EM, Lin NU, DiPiro PJ, et al. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol 2012;23:93-97.
27. Theriault RL, Carlson RW, Allred C, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3, 2013. Available at: NCCN.org. Accessed December 9, 2013.
28. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-3277.
29. Brown BK, Karasavvas N, Beck Z, et al. Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J Virol 2007;81:2087-2091.
30. Earle CC, Landrum MB, Souza JM, et al. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;26:3860-3866.
31. Australian Government Department of Human Services. Late stage metastatic breast cancer. Available at: http://www.medicareaustralia.gov.au/provider/ patients/late-breast-cancer.jsp. Accessed August 17, 2012.
32. National Collaborating Centre for Cancer. Advanced breast cancer: diagnosis and treatment. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009. NICE clinical guideline; no. 81.
33. Pegram M, Liao J. Trastuzumab treatment in multiple lines: current data and future directions. Clin Breast Cancer 2012;12:10-18.
34. Benner SE, Fetting JH, Brenner MH. A stopping rule for standard chemotherapy for metastatic breast cancer: lessons from a survey of Maryland medical oncologists. Cancer Invest 1994;12:451-455.
35. Baszanger I. One more chemo or one too many? Defining the limits of treatment and innovation in medical oncology. Soc Sci Med 2012;75:864-872.
36. Harrington SE, Smith TJ. The role of chemotherapy at the end of life: "when is enough, enough?". JAMA 2008;299:2667-2678.
37. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012;367:1616-1625.